Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triple-negative breast cancer in the elderly.
Shagisultanova E, Mayordomo J, Elias AD. Shagisultanova E, et al. Breast J. 2017 Nov;23(6):627-629. doi: 10.1111/tbj.12814. Breast J. 2017. PMID: 29112794 No abstract available.
Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E. Korobeynikov V, et al. Among authors: shagisultanova e. Breast Cancer Res Treat. 2019 Sep;177(2):369-382. doi: 10.1007/s10549-019-05329-2. Epub 2019 Jun 28. Breast Cancer Res Treat. 2019. PMID: 31254157 Free PMC article.
Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Stoen E, et al. Among authors: shagisultanova e. Breast Cancer Res Treat. 2021 Jun;187(3):883-891. doi: 10.1007/s10549-021-06132-8. Epub 2021 Feb 24. Breast Cancer Res Treat. 2021. PMID: 33625615 Free PMC article.
Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2.
Shagisultanova E, Crump LS, Borakove M, Hall JK, Rasti AR, Harrison BA, Kabos P, Lyons TR, Borges VF. Shagisultanova E, et al. Mol Cancer Ther. 2022 Jan;21(1):48-57. doi: 10.1158/1535-7163.MCT-21-0098. Epub 2021 Nov 2. Mol Cancer Ther. 2022. PMID: 34728571 Free PMC article.
Overall survival is the lowest among young women with postpartum breast cancer.
Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, Slattery ML, Baumgartner K, Schedin P, John EM, Borges VF. Shagisultanova E, et al. Eur J Cancer. 2022 Jun;168:119-127. doi: 10.1016/j.ejca.2022.03.014. Epub 2022 May 4. Eur J Cancer. 2022. PMID: 35525161 Free PMC article.
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.
Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Elias AD, et al. Among authors: shagisultanova e. NPJ Breast Cancer. 2023 May 20;9(1):41. doi: 10.1038/s41523-023-00544-z. NPJ Breast Cancer. 2023. PMID: 37210417 Free PMC article.
28 results